Bio-Path BPTH Stock
Bio-Path Price Chart
Bio-Path BPTH Financial and Trading Overview
| Bio-Path stock price | 2.92 USD |
| Previous Close | 1.56 USD |
| Open | 1.57 USD |
| Bid | 0 USD x 1200 |
| Ask | 0 USD x 800 |
| Day's Range | 1.52 - 1.65 USD |
| 52 Week Range | 1.18 - 4.48 USD |
| Volume | 39.36K USD |
| Avg. Volume | 25.84K USD |
| Market Cap | 13.13M USD |
| Beta (5Y Monthly) | 1.307042 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -33.63 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13 USD |
BPTH Valuation Measures
| Enterprise Value | 5.88M USD |
| Trailing P/E | N/A |
| Forward P/E | -0.863822 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.4422202 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -0.374 |
Trading Information
Bio-Path Stock Price History
| Beta (5Y Monthly) | 1.307042 |
| 52-Week Change | -56.34% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 4.48 USD |
| 52 Week Low | 1.18 USD |
| 50-Day Moving Average | 1.51 USD |
| 200-Day Moving Average | 2.05 USD |
BPTH Share Statistics
| Avg. Volume (3 month) | 25.84K USD |
| Avg. Daily Volume (10-Days) | 24.58K USD |
| Shares Outstanding | 7.96M |
| Float | 7.93M |
| Short Ratio | 3.41 |
| % Held by Insiders | 0.42% |
| % Held by Institutions | 8.12% |
| Shares Short | 80.3K |
| Short % of Float | 1.01% |
| Short % of Shares Outstanding | 1.01% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -56.26% |
| Return on Equity (ttm) | -100.45% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -15746000 USD |
| Net Income Avi to Common (ttm) | -15782000 USD |
| Diluted EPS (ttm) | -1.99 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 6.73M USD |
| Total Cash Per Share (mrq) | 0.85 USD |
| Total Debt (mrq) | 195K USD |
| Total Debt/Equity (mrq) | 2.14 USD |
| Current Ratio (mrq) | 5.65 |
| Book Value Per Share (mrq) | 1.144 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16230000 USD |
| Levered Free Cash Flow (ttm) | -10264250 USD |
Profile of Bio-Path
| Country | United States |
| State | TX |
| City | Bellaire |
| Address | 4710 Bellaire Boulevard |
| ZIP | 77401 |
| Phone | 832-742-1357 |
| Website | https://www.biopathholdings.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 10 |
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Q&A For Bio-Path Stock
What is a current BPTH stock price?
Bio-Path BPTH stock price today per share is 2.92 USD.
How to purchase Bio-Path stock?
You can buy BPTH shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bio-Path?
The stock symbol or ticker of Bio-Path is BPTH.
Which industry does the Bio-Path company belong to?
The Bio-Path industry is Biotechnology.
How many shares does Bio-Path have in circulation?
The max supply of Bio-Path shares is 787.35K.
What is Bio-Path Price to Earnings Ratio (PE Ratio)?
Bio-Path PE Ratio is now.
What was Bio-Path earnings per share over the trailing 12 months (TTM)?
Bio-Path EPS is -33.63 USD over the trailing 12 months.
Which sector does the Bio-Path company belong to?
The Bio-Path sector is Healthcare.
Bio-Path BPTH included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ Composite Total Return I XCMP | 19659.36 USD — |
-1.62
|
— — | 19598.88 USD — | 19861.56 USD — | — - | — — |
| NASDAQ Capital Market Composite RCMP | 114.55 USD — |
-2.27
|
— — | 114.09 USD — | 116.72 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}